Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor.

about

Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor.

Item

http://www.wikidata.org/entity/Q38727054

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Cell-based, bioluminescent ass ...... en PCSK9 and the LDL receptor.

@en

type

Item

label

Cell-based, bioluminescent ass ...... en PCSK9 and the LDL receptor.

@en

prefLabel

Cell-based, bioluminescent ass ...... en PCSK9 and the LDL receptor.

@en

P1476

Cell-based, bioluminescent ass ...... en PCSK9 and the LDL receptor.

@en

P2093

James J Cali

http://www.w3.org/2001/XMLSchema#string

Jolanta Vidugiriene

http://www.w3.org/2001/XMLSchema#string

Sarah J Duellman

http://www.w3.org/2001/XMLSchema#string

Thomas Machleidt

http://www.w3.org/2001/XMLSchema#string

P2860

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction

Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.

Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.

P304

1722-1729

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1194/JLR.D074658

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28611099

http://www.w3.org/2001/XMLSchema#string

P921

bioluminescence

P932

5538273

http://www.w3.org/2001/XMLSchema#string